Skip to main content
Signal8

Petros Pharmaceuticals, Inc. (PTPI) Form 10-Q — May 13, 2026

$PTPIForm 10-QFiled May 13, 2026, 5:02 PM ET0001104659-26-060359Original filing

Petros Pharmaceuticals, Inc. has experienced a net loss of $987,036 for the three months ended March 31, 2026, compared to a net loss of $2,260,022 for the same period in 2025. The decrease in net loss is primarily due to a reduction in selling, general and administrative expenses, which decreased by $431,170 or 30% from $1,458,349 in 2025 to $1,027,179 in 2026. The company's cash position as of March 31, 2026, is $4,352,450, down from $5,136,722 as of December 31, 2025.

Key figures

Eps
0
Revenue
0
Total Debt
2623135
Cash Position
4352450

Price after filing

1 day: 0.0%7 days: 0.0%30 days: 0.0%

Close on the filing date to close N calendar days later (from $0.01). Historical, not a forecast.

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.